

# **Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Trust Headquarters, Marlborough Street, Bristol, BS1 3NU. Interventional Cardiology Fellow, Associate Prof Cardiology.**

**Project Name:** Bristol Heart Institute Nurse Led ASCV and Lipid Prevention Model of Care

## **Project Summary:**

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) in response to the needs of the CW Partner.

This project aims to implement a local secondary care led secondary prevention clinic, focusing on supporting the discharge and onward management of secondary prevention patients, including first dose medicine optimisation, and subsequent transfer to primary care setting.

The CWP will be co-led by a Nurse band 7 and a Nurse band 6 alongside a multi-disciplinary team; including a consultant cardiologist (x2) and a Band 7 Management/Administrative Support, aiming to achieve:

1. Identification of sub-optimally treated ASCVD patients who are not achieving lipid levels as specified in local guidelines.
2. Identification of ASCVD patients who have previously not tolerated or refused alternative lipid modification therapies.
3. Review of treatment options and decision on next steps in collaboration with ASCVD patients.
4. Counsel and optimize ASCVD patients where appropriate.
5. Early identification of at-risk patients who have not had intervention in their health and wellbeing.
6. Identification of ASCVD patients, following risk assessment review, of ASCVD patients who are sub-optimally treated.
7. On-going ASCVD patients support and annual review to ensure CVD outcomes improve equitably.

## **Expected Benefits:**

Anticipated benefits for patients:

- Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
- Enhanced experience around ASCVD with ongoing management of the condition.
- Improved access to appropriate medication for suitable patients to preserve health and prevent long-term

events

- Easier access to lipid management care closer to home in the Primary Care setting.

The service could also act as a direct link for Primary Care to raise patient queries from proactive identification and gain support from a dedicated secondary prevention resource within secondary care. The long-term scope for this CWP is to incorporate the proactive case finding in primary care and build upon the clinic to meet the needs of primary care.

Anticipated benefits for organisation(s):

- Increased proportion of ASCVD ACS patients reviewed by secondary care
- Reduced unplanned presentations to secondary care in year 1 post-ACS
- Increased proportion of ASCVD patients receiving expert and timely review closer to home
- Increased proportion of patients receiving guideline-directed pharmacotherapy
- Improved collaborative working between primary and secondary care
- Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES

Anticipated benefits for Novartis:

- Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis's medicine
- Enhanced reputation, and supporting Novartis' vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation.

**Start Date & Duration:** November 2023, 15 Months.

---

**Source URL:** <https://www.novartis.com/uk-en/about/partnerships/collaborative-working/bristol-heart-institute-university-hospitals>

**List of links present in page**

- <https://www.novartis.com/uk-en/uk-en/about/partnerships/collaborative-working/bristol-heart-institute-university-hospitals>